April 2026 Research Update

This month added a clearer picture that enzyme replacement therapy can show measurable changes in Gaucher-related bone and marrow findings, while the amount of change can look different depending on what is measured and how large the study is. In a phase 4 study of velaglucerase alfa, the bone marrow burden score improved over 24 months, while the lumbar spine bone density score changed only slightly and was not statistically significant in that small group. Safety reporting across enzyme therapies was also explored using a large adverse-event database, but those patterns are considered signals that need confirmation rather than proof of cause and effect. [1] [2]

In people with type 1 Gaucher disease and bone involvement, velaglucerase alfa was linked with a significant improvement in bone marrow burden score over 24 months, which is a scoring approach used to track Gaucher-related marrow changes. The lumbar spine bone density Z-score moved from -1.93 to -1.76 in the study group, but this change was not statistically significant, while a separate pooled set of prior velaglucerase alfa trial data showed a statistically significant increase over 24 months. This helps separate two ideas: marrow-related measures may show clearer changes in a small cohort, while bone density changes may be harder to detect without larger datasets or longer follow-up. [1]

A separate analysis used FAERS (a US adverse-event reporting database) to compare reported safety signals for imiglucerase, velaglucerase alfa, and taliglucerase alfa. Infection-related report patterns were more prominent for imiglucerase and velaglucerase alfa, while a hepatic fibrosis signal was noted for taliglucerase alfa, and the typical time from starting a drug to an event differed across the agents. Because FAERS contains voluntary reports and does not prove that a drug caused an event, these results are best understood as a map of what should be studied more carefully, rather than a direct comparison of real-world risks. [2]

For people living with Gaucher disease, these studies add detail about what kinds of changes have been measured during enzyme replacement therapy and what kinds of safety questions are still being explored. The velaglucerase alfa results may matter now as additional evidence about how bone marrow and bone density measurements can behave over time in treated adults, although the study size was small and not all changes were clear within that cohort. The FAERS findings mainly matter as early research signals: they highlight specific side effects that were reported more often with certain products in the database, but they do not show that one therapy is safer or riskier for an individual person. [1] [2]

Several human studies this month focused on Gaucher disease as a condition that can involve multiple organs over time, sometimes in subtle ways that standard checks might miss. One study found that a sensitive heart ultrasound measurement (strain) was lower in Gaucher type 1 than in healthy controls and predicted worsening on a Gaucher severity score. Another study that followed people over years described gradual changes in movement signs, thinking skills, sleep, hearing, and specialized eye tests, while some routine eye measures stayed stable. [3] [4]

In a small cohort, left ventricular global longitudinal strain (a way of measuring how well the heart muscle shortens with each beat) was reduced in Gaucher disease type 1 compared with healthy controls, and it was the only independent predictor of worsening on the DS3 disease severity score. In plain language, this suggests that very early heart involvement may show up on more sensitive imaging measures before standard pumping measures look abnormal. The study does not show what to do with this information yet, but it supports ongoing research on whether strain could help identify progression earlier. [3]

In a prospective follow-up study (median about 37 months), participants showed progression in several nervous-system related areas, including worsening subtle parkinsonian signs and increasing non-motor symptom scores, with some developing epilepsy during follow-up. Sleep problems were common, and a larger share of people performed below expected levels in at least one thinking domain, especially memory-related tasks. Hearing loss was frequent in those tested and often worsened over time, while vision sharpness and a common retina scan stayed unchanged even though a more specialized retina function test was often abnormal. [4]

Two additional studies broadened the picture of where Gaucher-related biology may show up in other health settings, but the connections are less direct. A registry report of children with rare metabolic causes of interstitial lung disease included a small group with Gaucher disease, described common chest CT patterns, and noted that some received enzyme replacement therapy with no increase in respiratory support during treatment. A large population database study of intervertebral disc degeneration reported strong family clustering and mentioned a potential new link between Gaucher disease and disc degeneration, but details of that link were not provided in the summary. [5] [6]

A separate study in people with typical Parkinson's disease (not Gaucher disease) examined whether carrying certain GBA1 variants affected how symptoms changed over time. Results were not statistically significant after correcting for many comparisons, but there were hints of faster cognitive decline in variant carriers and faster worsening of some non-motor symptoms in the PD-risk group. This is relevant to Gaucher families because GBA1 is the Gaucher gene, but the study is about Parkinson's progression and needs replication before firm conclusions. [7]

For patients and caregivers, these studies mainly add understanding of how Gaucher disease can evolve across different body systems and how researchers are trying to measure change earlier and more precisely. The heart-strain and long-term follow-up findings may matter in the future if they are confirmed, because they point to tests that could potentially detect progression that is not obvious day to day. The lung registry and disc degeneration report are more descriptive and do not establish cause, but they widen awareness of less common areas being studied in Gaucher and related genetics. [3] [4] [5] [6] [7]

This month also brought several early-stage studies focused on new ways to measure Gaucher biology and new ideas for future treatments, but all of these are still in laboratory or computational stages. One group developed a dried blood spot lab test that measures a Gaucher marker (Lyso-GL1) alongside a Fabry marker, supporting higher-throughput screening approaches. Other studies used patient cells or recombinant enzymes to test ways to improve glucocerebrosidase function or delivery, and one computational study mapped genetic loci tied to Gaucher type 1 related traits. [8] [9] [10] [11]

A lab-method study reported a high-throughput approach to measure Lyso-GL1 (a blood marker often used in Gaucher research and monitoring) from dried blood spots, with verification on 20 samples. The method also measured Lyso-GL3, which is used in Fabry disease, allowing both markers to be checked at the same time. This matters as infrastructure research: it supports the idea that rare disease markers can be measured efficiently from small samples, but it does not by itself show how screening or monitoring should change. [8]

Two laboratory studies explored ways to increase glucocerebrosidase (GCase) activity where it is needed. In patient-derived Gaucher fibroblasts, a designed molecule called LYSOTAC was used to bring GCase to lysosomes, and researchers reported restored lysosomal GCase activity with increased breakdown of stored lipid. Separately, an in vitro study found that a Glu235Ser version of GCase had higher catalytic efficiency and stability than wild-type enzyme, and showed higher uptake and longer activity in macrophage-like cells, although the authors noted this could be influenced by glycosylation differences. [9] [10]

Two computational studies looked for biological connections and possible future treatment starting points. One used genomic modeling to identify 15 loci linked to Gaucher type 1 related traits and explored how certain missense variants might affect protein structure and stability, along with screening for possible related biomarkers. Another used bioinformatics to look for shared gene-expression features between Gaucher disease and melanoma, predicted several drug candidates, and tested one: colchicine reduced lipid accumulation in a Gaucher cell model. [11] [12]

For patients, these studies are best viewed as early building blocks rather than results that affect care now. The dried blood spot test work may matter later if it helps make biomarker testing easier or more widely available, but it was validated on a small set and was focused on lab performance rather than patient outcomes. The LYSOTAC, Glu235Ser enzyme, and colchicine findings were in cells or test systems, which helps clarify what is scientifically possible but does not tell us whether these approaches will be safe or effective in people. The genetic modeling work may help future research explain why Gaucher type 1 varies between people, but it does not yet translate into a new test or therapy. [8] [9] [10] [11] [12]